Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2023
Insights+: The US FDA New Drug Approvals in May 2023
Shots: The US FDA approved 15 NDAs and 3 BLA in May 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 54 novel products in 2023 In May 2023, the major highlights drugs were, Ayvakit approval for Indolent Systemic Mastocytosis, Rinvoq for Active Crohn's Disease PharmaShots has…
June 21, 2023
Disease of the Month - Scleroderma
Disease of the Month – Scleroderma
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research  Continuing the series for the disease of the month, PharmaShots brings this month a summary of the disease, Scleroderma, a rare neurological disease that affects…
June 8, 2023
Insights+ Key Biosimilars Events of May 2023
Insights+ Key Biosimilars Events of May 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, Celltrion’s Yuflyma (biosimilar, adalimumab) received the…
June 7, 2023
Insights+: EMA Marketing Authorization of New Drugs in April 2023
Insights+: EMA Marketing Authorization of New Drugs in April 2023
Shots: The EMA approved 8 New Chemical Entity (NCE) and 3 Biologic Drugs in April 2023, leading to treatments for patients and advances in the healthcare industry In April 2023, the major highlights drugs were Rinvoq’s Approval for active Crohn's Disease, Opzelura for non-segmental vitiligo with facial involvement in adults and adolescents PharmaShots has compiled…
May 25, 2023
Top Performing Drug – Trikafta/Kaftrio (May Edition)
Top Performing Drug – Trikafta/Kaftrio (May Edition)
Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Trikafta/Kaftrio as the top-performing drug of the month Trikafta is a combination of ivacaftor, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis in pediatric patients who have at least one…
May 24, 2023
Insights+: The US FDA New Drug Approvals in April 2023
Insights+: The US FDA New Drug Approvals in April 2023
Shots: The US FDA approved 6 NDAs and 4 BLA in April 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 36 novel products in 2023 In April 2023, the major highlights drugs were, Trikafta approval for children with cystic fibrosis, Qalsody for the treatment of amyotrophic…
May 17, 2023
Disease of the Month - Amyotrophic Lateral Sclerosis (ALS)
Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research  To continue the series for the disease of the month, PharmaShots brings this month a summary of the disease Amyotrophic Lateral Sclerosis (ALS), a rare…
May 11, 2023
Insights+ Key Biosimilars Events of April 2023
Insights+ Key Biosimilars Events of April 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Sandoz’s Hyrimoz (biosimilar, adalimumab) received EC’s…
May 3, 2023
Insights+: EMA Marketing Authorization of New Drugs in March 2023
Insights+: EMA Marketing Authorization of New Drugs in March 2023
Shots: The EMA approved 4 New Chemical Entity (NCE) and 5 Biologic Drugs in March 2023, leading to treatments for patients and advances in the healthcare industry In March 2023, the major highlights drugs were Reblozyl’s Approval for anemia in adult patients with non-transfusion-dependent beta thalassemia, Pombiliti for late-onset pompe disease PharmaShots has compiled a…
April 27, 2023
Top Performing Drug – Dupixent (April Edition)
Top Performing Drug – Dupixent (April Edition)
Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc. PharmaShots…
April 26, 2023
Load more